explore -WSS

explore

author：entertainment 2025-10-02 20:49:16 - browse：1174

Astrazeneca office building -- health policy coverage from STAT — AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Morphosys mixed study results for blood cancer drug

WSS

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

The pink breast cancer awareness ribbon needs a redesign

PBM reforms clear House panel

Telehealth options flood the market as retailers push virtual care

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Morphosys mixed study results for blood cancer drug

focus

explore

focus

Medical records are filled with copy

Does good food count as health care? Study aims to find out

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Anthos stroke drug appears safer than common blood thinner

Novavax promises a turnaround & Lilly roils the obesity market

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Wildfire smoke exposes gaps in outdoor worker protections

Telehealth options flood the market as retailers push virtual care

Malaria cases in Florida and Texas: Here’s what you need to know

FDA's Woodcock to retire early next year

explore

FDA's Woodcock to retire early next year

Telehealth options flood the market as retailers push virtual care

Weight loss drug Wegovy cuts risk of heart attacks in milestone trial

Traditional Chinese medicine benefits explored in new JAMA study

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Weight loss drug costs may need more research, senator suggests

focus

hotspot

Wikipedia

hotspot